Search research articles
Contact Us
Filters
Showing results (111-120 of 117) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 117 results.
Cancers
|
November 13, 2021
Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
Robert A Szczepaniak Sloane, Michael G White, Russell G Witt, et al.
Oncoimmunology
|
November 15, 2021
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanoma
Michael G White, Robert Szczepaniak Sloane, Russell G Witt, et al.
Nature
|
July 19, 2023
Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells
Yogesh Goyal, Gianna T Busch, Maalavika Pillai, et al.
Frontiers in Oncology
|
October 31, 2022
The immune landscape of undifferentiated pleomorphic sarcoma
Rossana Lazcano, Carmelia M Barreto, Ruth Salazar, et al.
Nature Cancer
|
February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma
Christina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Nature
|
June 15, 2022
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Christopher P Vellano, Michael G White, Miles C Andrews, et al.
Nature
|
January 10, 2023
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Christopher P Vellano, Michael G White, Miles C Andrews, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 117) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 117 results.
Cancers
|
November 13, 2021
Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
Robert A Szczepaniak Sloane, Michael G White, Russell G Witt, et al.
Oncoimmunology
|
November 15, 2021
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanoma
Michael G White, Robert Szczepaniak Sloane, Russell G Witt, et al.
Nature
|
July 19, 2023
Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells
Yogesh Goyal, Gianna T Busch, Maalavika Pillai, et al.
Frontiers in Oncology
|
October 31, 2022
The immune landscape of undifferentiated pleomorphic sarcoma
Rossana Lazcano, Carmelia M Barreto, Ruth Salazar, et al.
Nature Cancer
|
February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma
Christina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Nature
|
June 15, 2022
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Christopher P Vellano, Michael G White, Miles C Andrews, et al.
Nature
|
January 10, 2023
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Christopher P Vellano, Michael G White, Miles C Andrews, et al.
Page
of 12